A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial

Brian Eichner, Le Ann C Michaels, Kelsey Branca, Katrina Ramsey, Julie Mitchell, Cynthia D Morris, Lyle J Fagnan, Rowena J Dolor, Nancy Elder, David L Hahn, Donald E Nease, Jodi Lapidus, Ricardo Cibotti, Julie Block, Eric L Simpson, Brian Eichner, Le Ann C Michaels, Kelsey Branca, Katrina Ramsey, Julie Mitchell, Cynthia D Morris, Lyle J Fagnan, Rowena J Dolor, Nancy Elder, David L Hahn, Donald E Nease, Jodi Lapidus, Ricardo Cibotti, Julie Block, Eric L Simpson

Abstract

Background: Atopic dermatitis (AD) is a common, chronic skin disorder often beginning in infancy. Skin barrier dysfunction early in life serves as a central event in the pathogenesis of AD. In infants at high risk of developing AD, preventative application of lipid-rich emollients may reduce the risk of developing AD. This study aims to measure the effectiveness of this intervention in a population not selected for risk via a pragmatic, randomized, physician-blinded trial in the primary care setting.

Methods: Infant-parent dyads are recruited from a primary care practice participating through one of four practice-based research networks in Oregon, Colorado, Wisconsin, and North Carolina. Eligible dyads are randomized to the intervention (daily use of lipid-rich emollient) or the control (no emollient) group (n = 625 infants in each) and are followed for 24 months. The primary outcome is the cumulative incidence of physician-diagnosed AD and secondary outcomes include caregiver-reported measures of AD and development of other atopic diseases. Data collection occurs via chart review and surveys, with no study visits required. Data will be analyzed utilizing intention-to-treat principles.

Discussion: AD is a common skin condition in infants that affects quality of life and is associated with the development of other atopic diseases. If a safe intervention, such as application of lipid-rich emollients, in the general population effectively decreases AD prevalence, this could alter the guidance given by providers regarding routine skin care of infants. Because of the pragmatic design, we anticipate that this trial will yield generalizable results.

Trial registration: ClinicalTrials.gov: NCT03409367. Registered on 11 February 2018.

Keywords: Atopic dermatitis; Eczema; Emollient; Moisturizer; Practice-based research network; Pragmatic.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Pragmatic Explanatory Continuum Indicator Summary (PRECIS-2) wheel for aspects of the pragmatic trial. The investigators have quantified each of the nine PRECIS-2 domains along the “explanatory–pragmatic continuum”, where 1 = most explanatory and 5 = most pragmatic. Generally, pragmatic trials correspond with “real-world effectiveness trials” and explanatory trials correspond with “efficacy/mechanistic trials”
Fig. 2
Fig. 2
Organizational chart for the CASCADE study. CASCADE A Community-based Assessment of Skin Care, Allergies, and Eczema, Meta-LARC Meta-network Learning And Research Center, ORPRN Oregon Rural Practice-based Research Network, PCRC Primary Care Research Consortium, PI Principal Investigator, SNOCAP State Networks of Colorado Ambulatory Practices & Partners, WREN Wisconsin Research & Education Network
Fig. 3
Fig. 3
Standard Protocol Items: Recomvhmendations for Interventional Trials (SPIRIT) checklist including milestones of enrollment and data collection during the CASCADE study. AD atopic dermatitis, AE adverse events, CASCADE A Community-based Assessment of Skin Care, Allergies, and Eczema, CEQ Children’s Eczema Questionnaire, mAPI modified Asthma Predictive Index, mo months, PGH-7 Pediatric Global Health checklist, SAE serious adverse events, PCP Primary Care Provider

References

    1. Yaghmaie PKC, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428–433. doi: 10.1016/j.jaci.2012.10.041.
    1. Roduit C, Frei R, Depner M, Karvonen AM, Renz H, Braun-Fahrländer C, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171:655–662. doi: 10.1001/jamapediatrics.2017.0556.
    1. Kim MJ, Kang TW, Cho EA, Kim HS, Min JA, Park H, et al. Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area. Korea J Korean Med Sci. 2010;25:1828. doi: 10.3346/jkms.2010.25.12.1828.
    1. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150:593–600. doi: 10.1001/jamadermatol.2013.10271.
    1. Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5(2):202.
    1. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76:159–162. doi: 10.1136/adc.76.2.159.
    1. Horimukai K, Morita K, Narita M, Kondo M, Kabashima S, Inoue E, et al. Transepidermal water loss measurement during infancy can predict the subsequent development of atopic dermatitis regardless of filaggrin mutations. Allergol Int Off J Jpn Soc Allergol. 2016;65:103–108. doi: 10.1016/j.alit.2015.09.004.
    1. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol JEADV. 2012;26:1045–1060. doi: 10.1111/j.1468-3083.2012.04635.x.
    1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338–351. doi: 10.1016/j.jaad.2013.10.010.
    1. Macharia W, Anabwani G, Owili D. Effects of skin contactants on evolution of atopic dermatitis in children: a case control study. Trop Dr. 1991;21(3):104–106. doi: 10.1177/004947559102100305.
    1. Darmstadt GL, Saha SK, Ahmed ASMNU, Choi Y, Chowdhury MAKA, Islam M, et al. Effect of topical emollient treatment of preterm neonates in Bangladesh on invasion of pathogens into the bloodstream. Pediatr Res. 2007;61:588–593. doi: 10.1203/pdr.0b013e3180459f75.
    1. Kiechl-Kohlendorfer U, Berger C, Inzinger R. The effect of daily treatment with an olive oil/lanolin emollient on skin integrity in preterm infants: a randomized controlled trial. Pediatr Dermatol. 2008;25:174–178. doi: 10.1111/j.1525-1470.2008.00627.x.
    1. Pabst RC, Starr KP, Qaiyumi S, Schwalbe RS, Gewolb IH. The effect of application of Aquaphor on skin condition, fluid requirements and bacterial colonization in very low birth weight infants. J Perinatol. 1999;19:278–283. doi: 10.1038/sj.jp.7200157.
    1. Edwards WH, Conner JM, Soll RF, Vermont Oxford Network Neonatal Skin Care Study Group The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000 g. Pediatrics. 2004;113:1195–1203. doi: 10.1542/peds.113.5.1195.
    1. Nopper AJ, Horii KA, Sookdeo-Drost S, Wang TH, Mancini AJ, Lane AT. Topical ointment therapy benefits premature infants. J Pediatr. 1996;128:660–669. doi: 10.1016/S0022-3476(96)80132-6.
    1. Darmstadt GL, Badrawi N, Law PA, Ahmed S, Bashir M, Iskander I, et al. Topically applied sunflower seed oil prevents invasive bacterial infections in preterm infants in Egypt: a randomized, controlled clinical trial. Pediatr Infect Dis J. 2004;23:719–725. doi: 10.1097/01.inf.0000133047.50836.6f.
    1. Lane AT, Drost SS. Effects of repeated application of emollient cream to premature neonates’ skin. Pediatrics. 1993;92:415–419.
    1. Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63:587–593. doi: 10.1016/j.jaad.2009.11.011.
    1. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818–823. doi: 10.1016/j.jaci.2014.08.005.
    1. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134:824–830. doi: 10.1016/j.jaci.2014.07.060.
    1. Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials. 2017;18 [cited 2018 Oct 12]; Available from: .
    1. Mar A, Marks R. The prevention of atopic dermatitis. In: Williams HC, editor. Atopic dermatitis. Cambridge: Cambridge University Press; 2000. p. 205.
    1. Al-Naqeeb J, Danner S, Fagnan LJ, Ramsey K, Michaels L, Mitchell J, et al. The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC Consortium. J Am Board Fam Med JABFM. 2019;32:191–200. doi: 10.3122/jabfm.2019.02.180225.
    1. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. doi: 10.1136/bmj.h2147.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Leitenberger S, Hajar T, Simpson EL, von Kobyletzki L, Hanifin JM. Validation of a parent-reported diagnostic instrument in a U.S. referral population: the Childhood Eczema Questionnaire. Pediatr Dermatol. 2017;34:398–401. doi: 10.1111/pde.13139.
    1. Kleinman LC, Norton EC. What’s the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009;44(1):288–302. doi: 10.1111/j.1475-6773.2008.00900.x.
    1. Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. J Clin Epidemiol. 1999;52(1):19–26. doi: 10.1016/S0895-4356(98)00138-3.
    1. Silverberg JI, Patel N, Immaneni S, Rusniak B, Silverberg NB, Debashis R, et al. Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study. Br J Dermatol. 2015;173:1400–1404. doi: 10.1111/bjd.14031.
    1. von Kobyletzki LB, Berner A, Carlstedt F, Hasselgren M, Bornehag CG, Svensson Å. Validation of a parental questionnaire to identify atopic dermatitis in a population-based sample of children up to 2 years of age. Dermatology. 2013;226:222–226. doi: 10.1159/000349983.
    1. Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Discriminative properties of two predictive indices for asthma diagnosis in a sample of preschoolers with recurrent wheezing. Pediatr Pulmonol. 2011;46:1175–1181. doi: 10.1002/ppul.21493.
    1. Branum AM, Lukacs SL. Food allergy among children in the United States. PEDIATRICS. 2009;124:1549–1555. doi: 10.1542/peds.2009-1210.
    1. Forrest CB, Bevans KB, Pratiwadi R, Moon J, Teneralli RE, Minton JM, et al. Development of the PROMIS® Pediatric Global Health (PGH-7) measure. Qual Life Res. 2014;23:1221–1231. doi: 10.1007/s11136-013-0581-8.
    1. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326–1332. doi: 10.1111/bjd.12590.
    1. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol. 2001;144:104–110. doi: 10.1046/j.1365-2133.2001.03960.x.
    1. Rendell ME, Baig-Lewis SF, Berry TM, Denny ME, Simpson BM, Brown PA, et al. Do early skin care practices alter the risk of atopic dermatitis? A case–control study. Pediatr Dermatol. 2011;28:593–595. doi: 10.1111/j.1525-1470.2011.01384.x.
    1. Gao X, Simpson EL. Market trends in baby skin care products and implications for clinical practice. Pediatr Dermatol. 2014;31:734–738. doi: 10.1111/pde.12424.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir